Ignite Creation Date:
2024-05-05 @ 11:54 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00169091
Status:
TERMINATED
Last Update Posted:
2015-04-07
First Post:
2005-09-10
Brief Title:
Clozapine Versus Haloperidol for Treating the First Episode of Schizophrenia
Sponsor:
Harvard Medical School HMS and HSDM
Organization:
Harvard Medical School HMS and HSDM
Study Overview
Official Title:
Clozapine or Haloperidol in First Episode Schizophrenia
Status:
TERMINATED
Status Verified Date:
2015-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will examine the physical responses brought on by clozapine and haloperidol in people experiencing their first episode of schizophrenia
Detailed Description:
This is a longitudinal double blind 2- 5 year study of the clinical neuroendocrine and biochemical response to clozapine CLOZ and haloperidol HAL in a group of first episode schizophrenic RDC patients Within the protocol we compare the differential effects of the two drugs over the short term 12 weeks and the long-term 2-5 years we evaluate the relationship between change in prolactin level and clinical response of the patients and we search for biochemical predictors and correlates of clinical response To achieve the study aims we employ a drug-washout period a 12-week acute treatment period and an 88 - 260 week follow-up period
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| R01MH052376 | NIH | None | httpsreporternihgovquickSearchR01MH052376 |